Related Experiment Video

Updated: Jul 11, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment

Jian-Ting Zhang1, Yang Liu

  • 1Department of Pharmacology and Toxicology, Walther Oncology Center/Walther Cancer Institute and IU Cancer Center, Indiana University School of Medicine, 1044 W. Walnut Street, R4-166, IN 46202, United States. jianzhan@iupui.edu

Cancer Treatment Reviews
|September 15, 2007
PubMed

Insights

Proteomics is revealing new ways cancer cells resist chemotherapy. Understanding these drug resistance mechanisms in cancer cell lines may lead to combination therapies for better treatment outcomes.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Drug resistance significantly hinders effective cancer chemotherapy.
  • Identifying specific molecular mechanisms of drug resistance is challenging.
  • Proteomics offers a powerful approach to study drug resistance in cancer.

Purpose of the Study:

  • To review the application of proteomic tools in identifying drug resistance mechanisms.
  • To highlight recent advancements in understanding known and novel resistance pathways.
  • To analyze findings from proteomic studies in drug-selected cancer cell lines.

Main Methods:

  • Proteomic analysis of drug-selected model cancer cell lines.
  • Review and synthesis of existing proteomic studies on cancer drug resistance.
  • Comparative analysis of resistance mechanisms across different cell lines and drugs.

Main Results:

  • Proteomics has successfully identified novel and confirmed known drug resistance mechanisms.
  • Drug-selected cancer cell lines often exhibit multiple co-existing resistance mechanisms.
  • Common resistance mechanisms appear to be selected across various cancer cell lines.

Conclusions:

  • Proteomic strategies are crucial for elucidating complex drug resistance in cancer.
  • The presence of multiple resistance mechanisms suggests the need for multi-targeted therapies.
  • Future cancer treatment may require combination therapies to overcome drug resistance effectively.

More Related Videos

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors08:08

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors

Published on: February 27, 2015

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Proteomics01:33

Proteomics

A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...